SEC Form 4 · accession 0001470831-26-000636
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer E. Cook
Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 6:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 22, 2026 | A | 3,990 | $0.00 | A | 10,579 | D | |
| Common Stock | Jun 23, 2026 | S | 2,196 | $68.57 | D | 8,383 | D | |
| Common Stock | Jun 24, 2026 | M | 20,000 | $8.45 | A | 28,383 | D | |
| Common Stock | Jun 24, 2026 | M | 17,167 | $16.75 | A | 45,550 | D | |
| Common Stock | Jun 24, 2026 | S | 37,167 | $70.00 | D | 8,383 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $68.92 | Jun 22, 2026 | A | 5,277 | A | — | Jun 21, 2036 | Common Stock | 5,277 | 5,277 | D |
| Stock Option (Right to Buy)F5 | $8.45 | Jun 24, 2026 | M | 20,000 | D | — | Jun 22, 2032 | Common Stock | 20,000 | 19,000 | D |
| Stock Option (Right to Buy)F6 | $16.75 | Jun 24, 2026 | M | 17,167 | D | — | Jun 21, 2033 | Common Stock | 17,167 | 17,167 | D |
Explanation of responses
- F1Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
- F2Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
- F4The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
- F51/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
- F61/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.